Described herein is a fluorescent nanocomposite. The fluorescent nanocomposite structure may include a plasmonic nanostructure comprising having at least one localized surface plasmon resonance wavelength (λLSPR), at least one spacer coating, at least one fluorescent agent having a maximum excitation wavelength (λEX), and at least one peptide-loaded major histocompatibility complex (MHC) molecule (pMHC). The fluorescent nanocomposite structure has a fluorescent intensity that is at least 500 times greater than a fluorescent intensity of the at least one fluorescent agent alone.

An optical nano-biosensing system and a method thereof are provided. The optical nano-biosensing system includes a nano-plasmonic sensing device, a high-resolution analog-to-digital converter, a signal acquisition and processing device, and an intelligent electronic device. The nano-plasmonic sensing device further includes a light-source control circuit, a sample receiver, a light detector, and a signal-amplifying circuit. The sample receiver receives a sample. The light-source control circuit generates an incident light from a light source to be projected onto the sample receiver. The light detector detects an emergent light from the sample receiver to generate a detection signal. The signal-amplifying circuit converts the detection signal to generate an amplified signal. The high-resolution analog-to-digital converter digitizes the amplified signal to generate a digital signal. The signal calculator of the signal acquisition and processing device operates the digital signal to generate calculated information.

Aspects of the disclosure relate to methods and compositions useful for in vivo and/or in vitro enzyme profiling. In some embodiments, the disclosure provides methods of in vivo enzymatic processing of exogenous molecules followed by detection of signature molecules as representative of the presence of active enzymes associated with diseases or conditions. In some embodiments, the disclosure provides compositions and in vitro methods for localization of enzymatic activity in a tissue sample.

This disclosure provides methods and compositions for biomolecule corona analysis of biofluids. A biofluid may be contacted with a nanoparticle to form a biomolecule corona, and the composition of the resulting corona may be analyzed. Also provided are methods of preparing a biofluid for corona analysis by serial interrogation.

The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.

Provided by the inventive concept or nanoplastic or microplastic particles, reference standard materials including nanoplastic or microplastic particles, methods of using, and methods of preparing the same. Uses of the nanoplastic and/or microplastic particles of the inventive concept include tracking of nanoplastic and/or microplastic particle dispersion/distribution in environmental and/or biological systems, as well as in organisms that are within the environment.

The present disclosure provides a test strip for milk immunofluorescence assay (IFA) and use thereof, and relates to the technical field of test strip. The test strip of the present disclosure includes a sample pad, a conjugate pad, a nitrocellulose membrane, and a wicking pad assembled and pasted successively on a PVC backing card; fluorescent latex microsphere-labeled mixed antibodies are coated on the conjugate pad; anti-casein antibody (T1 line), anti-beta-lactoglobulin (BLG) antibody (T2 line), anti-alpha-lactalbumin (ALA) antibody (T3 line), anti-lactoferrin/anti-bovine serum albumin (BSA) antibody (T4 line), and rabbit anti-mouse IgG antibody (C line) are coated on the nitrocellulose membrane, where the T1, T2, T3, and T4 lines are test lines, and the C line is a control line. The test strip of the present disclosure accurately and quantitatively detects the content of casein, BLG, ALA, and lactoferrin/BSA in food, and features easy operation and high accuracy and sensitivity.

Provided herein is a rapid lateral flow device for detection of a target analyte in a liquid biological sample comprising a membrane strip, the membrane strip including: a matrix; a conjugate pad having at least one reporter vitrified into the matrix; one or more test sites including a covalently or electrostatically bound capture agent vitrified into or onto the matrix; and, optionally, a control line including one or more capture agents vitrified into or onto the matrix. Also provided are methods of rapid detection of a target analyte in a liquid biological sample.

The purpose of the present invention is to provide: a method which is for assessing the differentiation state of cells and by which the differentiation state of a wide variety of cells can be assessed; and gelatin nanoparticles which can be used in said method. The purpose is achieved by a method for assessing the differentiation state of cells, the method comprising a step for observing the expression of pyruvate dehydrogenase kinase 1 (PDK1) or mRNA (Pdk1) encoding pyruvate dehydrogenase kinase 1 in cells. Said method can be carried out by using gelatin nanoparticles which are used for assessing the differentiation state of cells and carry a probe capable of detecting Pdk1 or PDK1.

The present invention relates to intraoperative fluorescent imaging (IFI) used both pre-clinically using in-vivo models, as well as clinically to map sentinel lymph nodes in breast cancer, skin cancer, GI cancer, lung cancer, prostate cancer and several other cancers. IFI can be used to image solid tumors both non-specifically in hepatobiliary and breast cancers as well as in prostate and ovarian cancer. In one embodiment, two-dimensional resolution to 10 μm.sup.2 is possible with optical imaging, significantly higher than other imaging modalities. In one embodiment, the present invention relates to a series of self-assembled nanoparticles using HLA (hyaluronic acid) as both a polymeric backbone as well as targeting ligand. In some embodiments, the present invention relates to the synthesis of HLA conjugates, and the effect of variation of the hydrophobic ligand structure and conjugation level on nanoparticle self-assembly, size, ICG loading efficiency, and ICG fluorescence quenching and reactivation.